Equities Analysts Offer Predictions for Ocugen Q1 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Investment analysts at HC Wainwright cut their Q1 2025 EPS estimates for Ocugen in a research report issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.05) per share for the quarter, down from their prior estimate of ($0.04). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.11) EPS and FY2028 earnings at $0.21 EPS.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. During the same period in the previous year, the business posted ($0.03) earnings per share.

Separately, Chardan Capital upped their price target on shares of Ocugen from $6.00 to $7.00 and gave the company a “buy” rating in a report on Thursday.

Ocugen Stock Down 3.2 %

OCGN stock opened at $0.61 on Monday. The company has a market cap of $177.76 million, a P/E ratio of -3.39 and a beta of 3.88. Ocugen has a 52 week low of $0.55 and a 52 week high of $2.11. The company’s 50-day moving average price is $0.73 and its 200 day moving average price is $0.90. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On Ocugen

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new position in shares of Ocugen in the fourth quarter valued at $1,681,000. State Street Corp boosted its stake in Ocugen by 7.1% during the 3rd quarter. State Street Corp now owns 15,824,517 shares of the company’s stock valued at $15,701,000 after acquiring an additional 1,047,896 shares during the last quarter. Wellington Management Group LLP bought a new position in Ocugen during the 3rd quarter valued at $456,000. Geode Capital Management LLC boosted its stake in Ocugen by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 6,278,554 shares of the company’s stock valued at $6,231,000 after acquiring an additional 373,555 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in Ocugen by 258.8% during the 4th quarter. Jane Street Group LLC now owns 496,177 shares of the company’s stock valued at $399,000 after acquiring an additional 357,891 shares during the last quarter. Institutional investors and hedge funds own 10.27% of the company’s stock.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.